• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Corline Biomedical

18.00 SEK

+1.41 %

Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.41 %
-1.64 %
+13.56 %
+9.76 %
+11.11 %
+82.93 %
+24.57 %
+57.89 %
+81.97 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
470.4M SEK
Turnover
14.54K SEK
Revenue
7.65M
EBIT %
-192.81 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

16/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Regulatory press release5/12/2026, 6:50 PM

Kommuniké från årsstämma i Corline Biomedical AB (publ)

Corline Biomedical
Press release5/11/2026, 8:16 AM

Redeye: Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration

Corline Biomedical
Regulatory press release5/8/2026, 6:45 AM

Corline Biomedical AB offentliggör delårsrapport för perioden januari till mars 2026

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/21/2026, 3:18 PM

Corline Biomedical publicerar årsredovisning för 2025

Corline Biomedical
Regulatory press release4/7/2026, 12:36 PM

KALLELSE TILL ÅRSSTÄMMA I CORLINE BIOMEDICAL AB (PUBL)

Corline Biomedical
Press release2/18/2026, 10:21 AM

Redeye: Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence

Corline Biomedical
Regulatory press release2/17/2026, 7:35 AM

Corline Biomedical AB offentliggör bokslutskommuniké för perioden januari till december 2025

Corline Biomedical
Regulatory press release1/9/2026, 7:44 AM

CorlineCorline Biomedical stärker samarbetet med Kardium – genomför riktad emission och upptar lån från Kardium för att mångfaldiga produktionskapaciteten

Corline Biomedical
Press release11/26/2025, 3:31 PM

Förändringar i ersättningssystemet i USA möjliggör breddning av PFA-marknaden

Corline Biomedical
Press release11/19/2025, 7:25 AM

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical
Regulatory press release11/18/2025, 7:45 AM

Corline Biomedical AB offentliggör delårsrapport för perioden januari till september 2025

Corline Biomedical
Regulatory press release10/8/2025, 2:14 PM

Corline Biomedical genomför en riktad emission om 23 MSEK

Corline Biomedical
Press release10/1/2025, 3:30 PM

Kardium har inlett kommersialiseringen av Globe-systemet i USA

Corline Biomedical
Regulatory press release9/30/2025, 9:52 AM

Corline tecknar tioårigt licens- och leveransavtal med bedömt värde om cirka 2 miljarder kronor

Corline Biomedical
Press release9/2/2025, 8:29 AM

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Regulatory press release9/1/2025, 8:22 AM

Kardiums Globe-kateter med CHS™-coatning erhåller FDA-godkännande

Corline Biomedical
Press release8/27/2025, 9:54 AM

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical
Regulatory press release8/26/2025, 6:45 AM

Corline Biomedical AB offentliggör delårsrapport för perioden januari till juni 2025

Corline Biomedical
Press release7/2/2025, 1:11 PM

Corlines kund Kardium genomför finansiering om 250 miljoner USD för lanseringen av Globe®

Corline Biomedical
Regulatory press release5/15/2025, 9:00 AM

Kommuniké från årsstämma i Corline Biomedical AB (publ)

Corline Biomedical